Why Neurocrine Biosciences, Inc. (NBIX) stock rose 13.4% on Tuesday, November 3, 2026

Neurocrine Biosciences, Inc. (NBIX) closed at $164.85, up 13.42% on Tuesday, November 3, 2026, on volume of 4,042,002 shares (3.2× its 3-month average); market value about $16.80B.

What happened: primary sources

Events Nexqual found for NBIX on Tuesday, November 3, 2026 or the trading day before (November 2, 2026):

• Nov 2, 2026: Reported Q3 2026 results: adjusted EPS $3.29 vs consensus $2.75 (beat), revenue $1.12B. Guidance: INGREZZA net product sales guidance for full year 2026 was raised to a range of $2.9 billion to $2.925 billion. source
• Nov 3, 2026: Morgan Stanley: Target raised, Equal-Weight, price target $183 → $185
• Nov 3, 2026: RBC Capital: Target raised, Outperform, price target $187 → $190
• Nov 3, 2026: Canaccord Genuity: Target raised, Buy, price target $210 → $220
• Nov 3, 2026: Piper Sandler: Target raised, Overweight, price target $210 → $215

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on NBIX

NBIX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: NBIX results, November 2, 2026. Other big moves that day: November 3, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 4, 2026 at 09:52 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 4, 2026 at 09:52 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt